Compare EOG Resources Inc (EOG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Sanofi SA — how do they compare? EOG Resources Inc trades at $139.32 (market cap $73.22B), while Sanofi SA trades at $43.74 (market cap $103.94B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| EOG | SNY | |
|---|---|---|
Market Cap | $73.22B | $103.94B |
Sector | Energy | Health |
52-Week High | $149.89 | $52.34 |
52-Week Low | $101.78 | $41.33 |
Enterprise Value | $77.68B | $120.43B |
Dividend Yield | 2.97% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $138.01, down 1.15% on the day, with a bullish technical signal from moving averages and strong analyst support. The company maintains robust profitability with a net income margin of 23.39% and has beaten earnings estimates for the last three quarters. Recent news highlights its valuation discount and operational strength, with a consensus price target of $156.40 suggesting upside potential.
The outlook for EOG is positive, driven by consistent earnings beats, solid cash flow, and a favorable analyst consensus. Key risks include oil price volatility and elevated capital expenditures. The stock presents an opportunity for growth investors seeking exposure to a high-quality energy producer trading below target prices.
Sanofi (SNY) trades at $43.18, down 1.86% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 71.92% gross margins and 15.95% net income margin, supported by recent FDA approvals for Sarclisa and other pipeline developments. Cash flow remains positive at $49 million for 2025, though net cash flow has declined from previous years.
Investment outlook is mixed with analyst consensus leaning neutral (44% buy, 52% hold) amid regulatory scrutiny from EU antitrust probes. Key opportunities include Dupixent's growth and new drug approvals, while risks involve competition and patent expirations. The stock trades at reasonable valuations with P/E of 19.37 and P/B of 1.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
